Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

NCT01959698 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

CD20 Positive
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Stage I Diffuse Large B-Cell Lymphoma
Stage II Diffuse Large B-Cell Lymphoma
Stage III Diffuse Large B-Cell Lymphoma
Stage IV Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Carboplatin
DRUG: Carfilzomib
DRUG: Etoposide
DRUG: Ifosfamide
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
BIOLOGICAL: Rituximab

Sponsor

Roswell Park Cancer Institute

Collaborators

[object Object]
[object Object]